10578 SCIENCE CENTER DRIVE, SUITE 200, SAN DIEGO, CA
Announces Pricing of Upsized $90.0 Million Public Offering
News
Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial For The Treatment Of Relapsing-Remitting Multiple Sclerosis (RRMS)
Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Investor Presentation
Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
Shareholder votes
Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities to be Offered to Employees
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership